The Korean Journal of Medicine

  • 제93권1호
  • /
  • Pages.33-37
  • /
  • 2018
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

비알코올성 지방간염의 진단

Diagnostic Approach to Nonalcoholic Steatohepatitis

  • 유정주 (순천향대학교 의과대학 부천병원 내과) ;
  • 김상균 (순천향대학교 의과대학 부천병원 내과)
  • Yoo, Jeong-Ju (Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine) ;
  • Kim, Sang Gyune (Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine)
  • 발행 : 2018.02.01
⟨ 이전 논문 다음 논문 ⟩

초록

비알콜성 지방간은 최근에 우리나라에서도 매우 급격하게 유병률이 증가하고 있으며, 이 중 진행된 비알코올성 지방간염 및 섬유화가 동반되어 있을 가능성이 높은 환자를 선별하여 정밀하게 검사하고 치료를 적용하는 것이 요구된다. 현재까지 비알코올성 지방간염을 진단할 수 있는 가장 정확한 표준 검사법은 간 조직검사이지만 환자 및 의사 모두에게 쉽게 선택할 수 있는 검사법이 아니기 때문에, 간 조직검사를 대신하여 비침습적으로 비알코올성 지방간염의 진단 및 조직학적 중증도를 평가하고자 하는 노력이 영상의학 검사 및 생화학 검사 분야를 중심으로 진행되고 있다. 간과해서는 안 되는 중요한 문제는 지방간염 진단기준이 서양에서 도입된 방식을 따라가다 보니 진단에 요구되는 여러 가지 구성요소를 유전적, 환경적으로 다른 우리나라와 같은 동양인에도 획일적으로 적용되고 있다는 점이며 조직검사의 적절한 시기 및 병리 판독자 간의 일치도, 치료의 올바른 선택에 대하여 보다 적절한 근거가 필요한 실정이다.

키워드

참고문헌

  1. Quillin RC 3rd, Wilson GC, Sutton JM, et al. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation. Surgery 2014;156:1049-1056. https://doi.org/10.1016/j.surg.2014.06.075
  2. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554. https://doi.org/10.1002/hep.27368
  3. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014. https://doi.org/10.1111/j.1572-0241.1999.01451.x
  4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395. https://doi.org/10.1002/hep.20466
  5. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357. https://doi.org/10.1002/hep.29367
  6. Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209-1222. https://doi.org/10.1111/apt.12963
  7. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-1402.
  8. Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci 2016;61:1356-1364. https://doi.org/10.1007/s10620-016-4079-4
  9. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60:167-174. https://doi.org/10.1016/j.jhep.2013.07.042
  10. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.
  11. McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013;25:652-658. https://doi.org/10.1097/MEG.0b013e32835d72cf
  12. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in non-alcoholic fatty liver disease. Hepatology 2010;51:454-462. https://doi.org/10.1002/hep.23312
  13. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-835.
  14. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-1871. https://doi.org/10.1038/ajg.2012.331
  15. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740-751. https://doi.org/10.1038/ajg.2016.453
  16. Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014;59:1406-1414. https://doi.org/10.1002/hep.26761
  17. Williams CD, Stengel J, Asike MI, et al. Prevalence of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131. https://doi.org/10.1053/j.gastro.2010.09.038
  18. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-924.
  19. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873. https://doi.org/10.1002/hep.21327

피인용 문헌

  1. 청간플러스의 간기능 개선 효과 : 후향적 증례보고 8례 vol.41, pp.3, 2018, https://doi.org/10.22246/jikm.2020.41.3.542